Publications in collaboration with researchers from Volgograd Regional Clinical Oncology Dispensary № 1 (1)

2015

  1. Lapatinib or trastuzumab plus taxane therapy for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results of NCIC CTG MA.31

    Journal of Clinical Oncology, Vol. 33, Núm. 14, pp. 1574-1583